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We are investigating canine distemper virus (CDV) as a vaccine vector for the delivery of HIV envelope
(Env) that closely resembles the native trimeric spike. We selected CDV because it will promote vaccine
delivery to lymphoid tissues, and because human exposure is infrequent, reducing potential effects of
pre-existing immunity. Using SIV Env as a model, we tested a number of vector and gene insert designs.
Vectors containing a gene inserted between the CDV H and L genes, which encoded Env lacking most of
its cytoplasmic tail, propagated efﬁciently in Vero cells, expressed the immunogen on the cell surface,
and incorporated the SIV glycoprotein into progeny virus particles. When ferrets were vaccinated
intranasally, there were no signs of distress, vector replication was observed in the gut-associated
lymphoid tissues, and the animals produced anti-SIV Env antibodies. These data show that live CDV-SIV
Env vectors can safely induce anti-Env immune responses following intranasal vaccination.
& 2013 Elsevier Inc. All rights reserved.Introduction
Live-attenuated viral vaccines are used to effectively ﬁght impor-
tant human diseases, including measles and polio, demonstrating
that this vaccination strategy safely controls highly infectious viral
pathogens. Extending this vaccine approach to live-attenuated HIV
vaccines has been investigated using the rhesus macaque SIV AIDS
model. Vaccination of macaques with attenuated strains of SIV-
mac239, such as SIVmac239Δnef, protected a signiﬁcant number of
animals from disease by subsequent challenge with pathogenic virus
administered via mucosal or intravenous routes (Johnson et al., 1999;
Koff et al., 2006; Wyand et al., 1999). Unfortunately, translation
of this approach to an HIV vaccine is not practical as illustrated by
preclinical studies in macaques, which showed that even somell rights reserved.
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icine, Weill Cornell Medical
ethesda, MD, USA.highly attenuated SIV strains retained the ability to cause disease
(Baba et al., 1999). An alternative approach, which still exposes the
immune system to SIV/HIV proteins in the context of a viral infection,
is to deliver HIV immunogens using live replicating viral vectors.
Replicating vectors based on viruses including measles virus (MeV),
yellow fever virus (YFV), and poxviruses have entered preclinical
testing and clinical trials not only for vaccine development but also
for cancer therapy (Cattaneo et al., 2008; Draper and Heeney, 2010;
Liniger et al., 2007; Parks et al., in press). It is also important to note
that replicating viral vectors are used safely in a number of veterinary
vaccines (e.g. Newcastle disease viral vectors encoding avian inﬂu-
enza vaccine for poultry and chimeric YFV and West Nile Virus
vaccine for horses), demonstrating the feasibility of the approach
(Draper and Heeney, 2010).
Unique biological characteristics and availability of safe and
effective attenuated vaccines make morbilliviruses attractive can-
didates for HIV vaccine vector development. For example, mem-
bers of morbillivirus genus (e.g. MeV and CDV) are lymphotropic
because they use the signaling lymphocyte activation molecule
(SLAM) as a receptor (Tatsuo and Yanagi, 2002). Live attenuated
MeV and CDV vaccines also have a long-standing record of safety
Fig. 1. (A) Schematics of the CDV genomic clone and rCDV-SIVEnvΔct4 and rCDV-
SIVEnvΔct6 vectors. The CDV genomic clone contains six structural protein genes
that are separated by untranslated regions (UTR). Length of UTR ranges from 100 to
200 nucleotides except for the M/F UTR that is 495 nucleotides. The genomic cDNA
was cloned in pBluescript II SK(+/) with ﬂanking T7 promoter, hepatitis D virus
(HDV) ribozyme, and T7 polymerase terminator sequences. The SIVmac239 EnvΔct
gene was inserted before F in rCDV-SIVEnvΔct4 or after H in rCDV-SIVEnvΔct6 and
rCDV-SIVEnvΔct6UNC vectors. In each of the Env vectors, an extra F/H UTR was
introduced. (B) Map of full-length and truncated SIVmac239 Env. The 879 amino
acid Env protein consists of a surface unit (amino acids 1–693), a TM domain
(amino acids 694–715), and CT (amino acids 716–879). The EnvΔct lacks the
C-terminal residues 721–879. In the EnvΔctUNC, the furin cleavage signal R N K R
was mutated to S N K S.
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protection (Dine et al., 2004). Because live attenuated MeV
vaccines are safe and immunogenic, they have been investigated
as vaccine delivery vectors for a number of infectious diseases
including dengue virus, West Nile virus, and HIV (Brandler et al.,
2007; Brandler and Tangy, 2008; Despres et al., 2005; Guerbois
et al., 2009; Wang et al., 2001) producing promising preclinical
data. However, use of MeV vectors for human vaccines might be
constrained by prevalent anti-MeV immunity induced by universal
MeV vaccination programs and outbreaks of natural infection in
some areas.
Pre-existing anti-MeV humoral immunity is directed against
the only MeV serotype. This precludes use of rare serotype viruses
as vectors, which has been a strategy applied to other viral vector
systems (Mingozzi et al., 2013; Santra et al., 2009; Stephenson
et al., 2012). Thus, to minimize the effect of pre-existing anti-MeV
immunity, we are investigating attenuated CDV as a replicating
vector. CDV and MeV are antigenically related, but MeV antiserum
has limited neutralization activity against CDV (Miest et al., 2011).
Other CDV characteristics also are advantageous for vector
development. For example, live CDV vaccines have been used
safely to vaccinate dogs for decades and the attenuated stain can
be used as the basis for a vector. Also, no human diseases are
linked convincingly to CDV exposure (Rima and Duprex, 2006). In
fact, some early clinical investigation of experimental MeV vac-
cines was conducted with live attenuated CDV, and the results
showed that CDV could be injected into non-human primates and
humans without causing diseases (Hoekenga et al., 1960; Schwarz
and Anderson, 1965). Although not known to cause disease in
humans, CDV recently was associated with several instances of
disease in nonhuman primates (Qiu et al., 2011; Sakai et al., 2013;
Sun et al., 2010). It is important to note that a range of primates
cells are permissive for CDV infection in vitro, demonstrating
that it can be used as a delivery vector (Seki et al., 2003). CDV
also has the potential to be used as a mucosal vaccine delivery
vector, although subcutaneous or intramuscular injections are
conventional routes for live attenuated CDV vaccination. The virus
naturally infects through aerosol transmission and swiftly spreads
to gut-associated lymphoid tissues (GALT) (von Messling et al.,
2004a) thus favoring induction of immune responses in lymphatic
cells underlying the gut mucosal surface. Such immune responses
could be important for a vaccine to prevent depletion of gut CD4+
cells during acute HIV infection (Trono et al., 2010).
CDV is a paramyxovirus, and like all members of this family it
has non-segmented RNA genome of negative polarity. The genome
contains 6 transcription units arranged in order 3′ N–P–M–F–H–L
5′ (McIlhatton et al., 1997; Sidhu et al., 1993) that are separated
by intergenic regions, which range in length from 100 to 500
nucleotides (nt) and contain cis-acting signals that control mRNA
synthesis and processing (Anderson and von Messling, 2008).
Using reverse genetics systems similar to those described before
(Gassen et al., 2000; Parks et al., 2002), we developed a recombi-
nant CDV from an attenuated Onderstepoort strain. Since the
1940s, live attenuated Onderstepoort CDV has been widely used
in canine vaccines to safely and effectively control distemper in
dogs (Ehmer et al., 1948; Haig, 1948) and other domestic and
exotic carnivore animal species (Wimsatt et al., 2001).
Our goal is to develop a live vaccine vector capable of safely
delivering trimeric HIV envelope (Env) immunogens. We are
pursuing this objective because the Env spike is the only known
target of antibodies that neutralize HIV (Kwong and Mascola,
2012) and it follows that a vaccine should deliver an immunogens
that imitates the oligomeric structure on the HIV particle (Forsell
et al., 2009). Accordingly, we have developed prototype CDV
vectors that express SIV Env, which can be advanced for future
testing in the rhesus macaque SIV challenge protection model(Koff et al., 2006). Env is a type I membrane glycoprotein that is
synthesized as a precursor protein (gp160), which is cleaved by
furin protease to produce noncovalently linked gp120–gp41 het-
erodimers, which are assembled into a functional trimeric spike
(Checkley et al., 2011). Studies have shown that mature trimeric
Env exposes fewer structures recognized by non-neutralizing
antibodies suggesting that a correctly conﬁgured glycoprotein
spike might be a more effective immunogen (Chakrabarti et al.,
2011; Moore et al., 2006). Unfortunately, developing vectors that
express full-length gp160 Env generally is difﬁcult because the
protein has cytotoxic properties (Wyatt et al., 2008), thus we have
tested a number of vector and immunogen designs to identify
a combination that balances expression of a membrane-bound
trimer with genetic stability needed to propagate the vector. Our
results show that CDV encoding a functional SIV spike can be
produced if the Env cytoplasmic tail (CT) is truncated and protein
is expressed from a transcription unit inserted between the H and
L genes. Finally, we found that a CDV vector encoding Env could be
safely administered to ferrets by intranasal administration and
that a single dose elicited Env-speciﬁc antibody responses.Results
Expression of membrane-anchored Env immunogen by CDV vectors
Our objective was to develop a CDV vector that efﬁciently
expressed Env spikes on the surface of infected cells. The ﬁrst
vector we constructed was designed to encode full-length SIV-
mac239 Env from a gene inserted into the CDV genome between
M and F genes (4th position, Fig. 1A). After multiple unsuccessful
attempts to rescue this vector, we removed 159 amino acid codons
from the SIV Env gene so it encoded just a 5-amino acid CT
(Fig. 1B). After this modiﬁcation, the rCDV-SIVEnvΔct4 vector
was rescued, but was found to propagate poorly on Vero cells.
Fig. 2. CPE induced by rCDV-SIVEnvΔct4 on Vero (A), GHOST (B) and HOS (C) cells. Small plaques were induced on Vero and HOS at 3 DPI. Extensive cell fusion and
detachment were observed in GHOST cells at 1 DPI. Infected cells shown here were immunostained with SIV Env-speciﬁc antibody KK65.
Fig. 3. Growth kinetics of rCDV-empty, rCDV-SIVEnvΔct6, and rCDV- SIVEnvΔc-
t6UNC vectors. Vero cells were infected at MOI 1. From 12 to 72h after infection
started, cells and medium were harvested and cells were lysed by freeze-thaw
treatment. The lysates were clariﬁed and used to infect Vero cells for conducting
plaque assays. Average PFU titers were calculated from duplicate wells. The rCDV-
SIVEnvΔct6, rCDV-SIVEnvΔct6UNC, and rCDV-empty reached comparable peak
titers although the Env vectors took approximately 24 h longer to achieve the
highest titer.
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with the antibody KK65, which recognizes the gp120 V1 region of
the Env (Fig. 2A).
Because rCDV-SIVEnvΔct4 grew poorly on Vero cells but expressed
Env, we speculated that the vector might propagate more efﬁciently
on cell lines that express SIV/HIV coreceptors. When we infected
GHOST cell, which is a human osteosarcoma cell line modiﬁed to
express the human CD4 and CCR5 HIV coreceptors (Cecilia et al., 1998),
large syncytium formed rapidly within 24 hours post infection
(HPI) (Fig. 2B) indicating that Env was functional and was mediating
efﬁcient cell-to-cell fusion in the monolayer. To determine if the CDV
particles contained Env trimers that were capable of directing infec-
tion, we conducted two additional experiments. First, we infected HOS
cells with rCDV-SIVEnvΔct4. HOS cells are the progenitor of GHOST
and do not express HIV coreceptors. HOS cells supported very limited
vector propagation similar to Vero cells (Fig. 2C), which suggested that
Env might be directing more efﬁcient infection of CD4+/CCR5+ cells
as well as mediating more extensive cell-to-cell fusion. We then
generated an rCDV vector carrying an uncleavable form of Env
(SIVEnvΔctUNC), which has a mutation in the furin cleavage signal.
Vector rCDV-SIVEnvΔct4UNCwas rescued, but it propagated poorly on
both Vero and GHOST cells. Poor growth and low level of CPE
displayed on GHOST cells by rCDV-SIVEnvΔct4UNC indicated that
functional Env was required to see the more fusogenic phenotype.
Although it was encouraging to ﬁnd that the rCDV-SIVEnvΔct4
expressed an SIV Env spike that assumed a functional conforma-
tion, poor replication on Vero cells would make it impractical to
advance this vector further as a vaccine candidate since it could
not be grown efﬁciently on a cell substrate suitable for vaccine
manufacturing. We speculated that down regulating Env expres-
sion might restore more efﬁcient vector propagation directed
by CDV F and H, and accordingly, made new vectors in which
the cleavable and uncleavable SIVEnvΔct was shufﬂed 5′ in the
genome to the 6th position between H and L genes (Fig. 1). Both
rCDV-SIVEnvΔct6 and rCDV-SIVEnvΔct6UNC were recovered and
both propagated more efﬁciently on Vero cells. Replication kinetics
in Vero cells were similar for both EnvΔct6 viruses and they
reached peak titer later than the rCDV-empty vector, peaking at 60
as opposed to 36 HPI. Nonetheless, the peak titers were similar
among all three viruses (Fig. 3).Poor propagation of SIVEnvΔct4 vectors in Vero cells was associated
with reduced CDV F expression
Because there was a prominent effect on CDV propagation
caused simply by moving the Env gene from between M and F to a
location between H and L, we further evaluated protein expression
from the two types of vectors. Western blot analysis was used to
quantify SIV Env and CDV structural proteins N (nucleoprotein),
M (matrix protein), and F (fusion glycoprotein) in infected cellextracts and in the medium supernatant. Env was detected with
anti-gp120 antibody (KK65).
In both the cell-free fractions (Fig. 4A) and cell lysates (Fig. 4B),
bands consistent in size with cleaved gp120 and a larger uncleaved
precursor were seen in lanes 2 and 3 indicating that furin cleavage
was not 100% efﬁcient during Env processing. Only the larger
precursor protein was seen in lane 4 as predicted since the protein
encoded by rCDV-SIVEnvΔct6UNC lacks the furin cleavage site.
Interestingly, the 120 kDa protein was more prominent in cell-free
fractions of both rCDV-SIVEnvΔct4 and rCDV-SIVEnvΔct6, suggest-
ing that the majority of Env is cleaved if it is incorporated into
CDV particles that bud from the cell. More of the uncleaved Env
precursor was evident in the cell-associated fraction. These results
also indicate that Env expression and cleavage are not signiﬁcantly
inﬂuenced by the gene insert position.
In infected Vero cell cultures, CDV N, M, and F was detected if
infection was conducted with rCDV-SIVEnvΔct6 or rCDV-SIVEnvΔc-
t6UNC, demonstrating that the Env gene insert did not signiﬁcantly
interfere with expression of the upstream transcription units (Fig. 4A
and B). Because expression of Env and CDV structural proteins were
undetectable in Vero cells infected with rCDV-SIVEnvΔct4 (data not
shown), infected GHOST cells were analyzed (Fig. 4A and B, Lane 2).
The results showed that Env, N, and M were expressed by rCDV-
SIVEnvΔct4, but quantities of F were below detectable limits.
To determine if the F expression defect was speciﬁc to GHOST cells
or the rCDV-SIVEnvΔct4 vector, GHOST cells were infected with
rCDV-empty and the three rCDV-SIV Env vectors (Fig. 4C). The results
showed that the defect in F expression was speciﬁc for the rCDV-
SIVEnvΔct4 vector (Fig. 4C, Lane 2). The nucleotide sequence
of the rCDV-SIVEnvΔct4 vector was conﬁrmed indicating that the
Fig. 4. Western blot analysis of viral proteins. (A) Cell-free Env, N, M, and F from infected GHOST (for rCDV-SIVenvΔct4) or Vero (for the other viruses) cells; (B) Env, N, M,
and F from cell lysates prepared from infected GHOST (for rCDV-SIVenvΔct4) or Vero (for the others) cells; (C) F protein expression in infected GHOST cells. Lanes 1, 2, 3, and
4 represent rCDV-empty, rCDV-SIVEnvΔct4, rCDV-SIVEnvΔct6, and rCDV-SIVEnvΔct6UNC. F protein was undetectable in rCDV-SIVEnvΔct4 infected GHOST cells.
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Furthermore, this suggested that some element of the vector design
was responsible for poor F expression (see Discussion) and that this
also caused poor growth rCDV-SIVEnvΔct4 on Vero cells.
SIV EnvΔct is anchored on the cell membrane and incorporated into
virion particles
We concentrated on further characterization of rCDV-SIVEnvΔct6
and rCDV-SIVEnvΔct6UNC since the rCDV-SIVEnvΔct4 vectors failed
to propagate in Vero cells and was not a practical candidate for use as
a vaccine. To assess cellular distribution and conﬁrm incorporation
of Env at the cell surface, we performed confocal microscopy on
Vero cells infected with rCDV-SIVEnvΔct6 and rCDV-SIVEnvΔct6UNC.
Antibody staining was done using permeabilized or non-permeab-
ilized cells to help differentiate intracellular and extracellular plasma
membrane-associated proteins. Detection of the intracellular protein
F-actin with labeled phalotoxins was used to monitor the speciﬁcity
of staining under permeable and nonpermeable conditions. Both
F-actin (green) and SIV Env (red) were stained when cells were
permeabilized with TritonX-100 (Fig. 5A and C). When cells were not
permeabilized, F-actin staining was undetectable while SIV Env
clearly was present on the plasma membrane (Fig. 5B and D).We also evaluated whether functional Env was incorporated
into rCDV-SIVEnvΔct6 particles. To do this, CD4+/CCR5+ GHOST
cells were infected with vector that was preincubated with
neutralizing quantities of immune ferret serum that was speciﬁc
for CDV F and H. In the absence of neutralizing CDV antiserum, the
rCDV-SIVEnvΔct6UNC vector infected GHOST cells (Fig. 6A) while
CPE was blocked when the virus was preincubated with the ferret
serum (Fig. 6B). This result clearly showed that the antiserum
effectively blocked infection dependent on F and H. In contrast, the
CDV-speciﬁc serum did not block rCDV-SIVEnvΔct6 infection of
GHOST cells, although less CPE was observed (Fig. 6C and D).
Infections also were performed on Vero cells (not shown) con-
ﬁrming that the antiserum effectively blocked infection mediated
by F and H. These results demonstrate that cleavable SIV EnvΔct
expressed by the rCDV vector was incorporated into virion
particles in a functional conﬁguration.
rCDV-SIVEnvΔct6 replicates in the ferret gut-associated lymphoid
tissues (GALT)
One of the primary reasons for evaluating CDV as a delivery
vector was that it naturally infects via respiratory mucosal surfaces
and targets the GALT as a site of replication (Langlois, 2005;
Fig. 5. Cellular localization of SIV Env in Vero cells infected with rCDV-SIVEnvΔct6 (A and B) or rCDV-SIVEnvΔct6UNC (C and D). Infected Vero cells were stained with
SIVEnv-speciﬁc antibody (KK17) under permeabilizing (A and C) and non-permeabilizing (B and D) conditions. Plasma membrane staining of Env (red) is evident in panels B
and D. F-Actin staining (green) was used as an intracellular protein control. F-Actin staining was absent from cells that were not permeabilized (B and D), indicating that the
cell ﬁxation preserved the integrity of the plasma membrane.
Fig. 6. The rCDV-SIVEnvΔct6 vector can infect GHOST cells through CD4/CCR5 coreceptors. To determine if SIV Env could direct infection, CDV-speciﬁc ferret antiserum was
used to block virus entry directed by F and H. The top panels (A and B) show GHOST cells infected by rCDV-SIVEnvΔct6UNC before (A) and after (B) incubation with anti-CDV
ferret serum. The monolayer in panel B was protected from infection demonstrating that the ferret serum blocked entry through CDV F and H. The bottom panels show
infections of rCDV-SIVEnvΔct6 without serum incubation (C) and after serum incubation (D). The ferret serum reduced but did not block infection (D) indicating that SIV Env
could direct infection. Cells were stained with CDV N-speciﬁc antibody.
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stimulate the mucosal immune system through vaccination by a
mucosal route, and it would deliver immunogen to the GALT
stimulating immune responses regionally in areas where SIV and
HIV replicate. We inoculated ferrets by the intranasal route and
then monitored infection in a number of tissues including gastro-
intestinal sections rich in Peyer's patches (PP) and mesenteric
lymph nodes (MLN) at days post infection (DPI) 1, 7, and 21. The
results showed that infectious rCDV-empty and rCDV-SIVEnvΔct6
was recovered from PP and MLN at DPI 7 but not at DPI 1 and 21
(Table 1). Infectious virus was not recovered from the nasal
turbinates, suggesting that it migrated away from the inoculation
site shortly after administration. Variations in recovery of infec-
tious virus were observed among different animals at DPI 7, which
is expected since these are outbred animals that might respond
differently to infection. These results demonstrated that the rCDV
vector replicated without causing illness in the animals and that
the SIV Env gene did not interfere signiﬁcantly with virus spread
from the intranasal inoculation site to the PP and MLN.
To determine if rCDV-SIVEnvΔct6 infection induced immune
responses, we ﬁrst quantiﬁed CDV-neutralizing serum antibodies.Table 1
Titers (in PFU) of infectious virus recovered from in ferret tissues. Mesenteric
lymph node (MLN), Peyer's patch enriched intestine (PP), and nasal turbinate (NT)
were harvested at 7 DPI and homogenates were prepared. Infectious virus in the
homogenates was quantiﬁed by plaque assay using Vero cells. Anti-CDV N antibody
staining was used to enhance plaque detection. Titers are expressed as PFU per
gram of tissue.
Group NT PP MLN
Naïve 0 0 0
Parental rCDV 0 1102 1.55103
0 0 7.05103
rCDV-coSIVenvΔct6 0 4.9103 3103
0 0 1102
Table 2
Anti-CDV neutralizing antibody titers in vaccinated ferrets. Neutralization titers
were determined post-infection at days 1, 7 and 21. Data for individual animals is
provided.
Group DPI 1 DPI 7 DPI 21
Naïve o8 o8 o8
rCDV-empty o8 8 512
o8 8 512
rCDV-SIVEnvΔct6 o8 o8 512
o8 8 512
Fig. 7. Intranasal vaccination of rCDV-SIVEnvΔct6 induced Env-speciﬁc antibody in ferre
antibody for detecting SIVEnv in GHOST cell monolayers. The GHOST cells were infected
SIVEnvΔct6. (B) Serum from ferrets vaccinated with rCDV-empty. Positive red stainingSerum samples collected prior to vaccination were conﬁrmed to be
free of anti-CDV neutralizing antibodies. At DPI 1, CDV neutraliza-
tion titers were below 1:8, which was the lowest dilution used in
the assay. CDV neutralization activity started appearing at DPI 7
(1:8 serum dilution) and was detected in animals vaccinated with
rCDV-empty or the vector encoding Env. Titers rose up to 1:512 for
21 DPI (Table 2). The SIV Env gene insert did not seem to diminish
the anti-CDV antibody response induced by rCDV-SIVEnvΔct6
virus at both DPI 7 and 21. The temporal appearance and range
of anti-CDV antibody titers for both rCDV-empty and rCDV-
SIVEnvΔct6 are consistent with those elicited by live CDV vaccines
in other studies (Pare et al., 1999; Wimsatt et al., 2001).
To determine if antibody against SIV Env was induced, ELISA
and immunostaining was performed with serum harvested at DPI
21. For the immunostaining assay, the DPI 21 ferret serum was
used to stain GHOST cell monolayers infected with a VSV-SIV Env
vector that expresses the same SIVmac239 Env in place of the
natural VSV glycoprotein (G). Serum from animals vaccinated with
rCDV-SIVEnvΔct6 stained cells expressing SIV Env (Fig. 7A).
In contrast, serum from animals infected with rCDV-empty were
negative (Fig. 7B). When ELISA was conducted, serum from
animals vaccinated with rCDV-SIVEnvΔct6 produced approxi-
mately 6 folds higher OD values compared to serum from animals
vaccinated with rCDV-empty (Fig. 8). Naïve ferret serum served
as background control and produced OD reading similar to
those obtained from animals vaccinated with rCDV-empty (Fig. 8).ts. Serum from vaccinated ferrets was collected at 21 DPI and was used as primary
with a VSV vector encoding SIV Env. (A) Serum from ferrets vaccinated with rCDV-
in panel A indicates that SIV Env antibody was present in the ferret serum.
Fig. 8. Quantiﬁcation of Env antibodies in ferret serum. ELISA plates were coated
with SIV Env gp130 and diluted serum samples collected at 21 DPI from an
unvaccinated ferret (n¼1) or animals vaccinated with rCDV-empty (n¼2) or
rCDV-SIVEnvΔct6 (n¼2) were used as primary antibody for the Env antigen
detection. Average OD values were calculated for the two animals in each virus-
vaccinated group.
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Fig. 9. SIVsmE660 neutralizing antibody titers in vaccinated ferret serum. Inhibitory dose (ID50) titers were measured using pseudoviruses containing from a neutralization-
sensitive strain (SIVsmE660/CG7G; left panel) or more neutralization resistant variants (SIVsmE660/CG7V; right panel). SIV neutralizing antibodies were detected in DPI21
antiserum from the two ferrets vaccinated with rCDV-SIVEnvΔct6. These sera were also positive for Env antibodies by cell monolayer staining (Fig. 7) and ELISA (Fig. 8).
X. Zhang et al. / Virology 446 (2013) 25–36 31These results indicated that rCDV-SIVEnvΔct6 elicited SIV Env-
speciﬁc binding antibodies.
To determine if the anti-Env antibodies evoked by rCDV-
SIVEnvΔct6 vaccination had SIV-neutralizing activity, Pseudovirus
neutralization assays were performed using ferret serum and
TZM-bl reporter cells. Neutralization titers are expressed as ID50
value that is the serum dilution at which relative light units (RLU)
were reduced by 50% compared to virus control wells (Hoffenberg
et al., 2013). Neutralizatiing antibodies were detected in the 21 DPI
serum from two ferrets vaccinated with rCDV-SIVEnvΔct6 as
indicated by the ID50 values signiﬁcantly above the background
from the serum of naïve animals and animals vaccinated with
rCDV-empty vector (Fig. 9). The two positive sera showed 2 to
3 fold higher neutralization antibody ID50 titers against the CG7G
SIVsmE660 Env pseudovirus compared to that of the CG7V,
consistent with the known neutralization sensitivity of these two
SIV isolates (Lopker et al., 2013). Both serum samples did not
neutralize pseudovirus containing MLV Env, conﬁrming SIV speci-
ﬁcity of the neutralizing antibodies (data not shown).Discussion
We developed a prototype replication-competent CDV vector
for delivering membrane bound SIV Env. The vector is based on an
attenuated canine vaccine strain and was found to induce Env
antibody responses after intranasal vaccination of ferrets. Impor-
tantly, the vector replicated and spread in this permissive host
without causing observable adverse reactions or fever.
Our intention is to use CDV-SIV Env as a model to help design
rCDV vectors for delivering HIV Env immunogens in an authentic
trimeric conﬁguration, which presents antigenic determinants
recognized by neutralizing antibodies. As has been observed
before for MVA vectyor (Wyatt et al., 2008), we found it neces-
sary to delete most of the CT of SIV Env to achieve acceptable
expression, vector propagation and gene stability. Fortunately, it is
known that deletion or replacement of the Env CT does not result
in loss of function of the Env trimer ectodomain (Postler and
Desrosiers, 2013), providing evidence that the truncated form of
the membrane-bound immunogen will display relevant epitopes.
Although we have used a C-terminal Env truncation to improve
our rCDV-SIVEnv vector, replacement of the HIV or SIV Env CT
with heterologous sequence also has been used successfully in
other negative-strand RNA virus vectors (Johnson et al., 1997;
McKenna et al., 2003; Mourez et al., 2011). Although our primary
focus has been to develop rCDV expressing membrane-bound Env
immunogens that possess structural and functional similarities to
native Env on virions and infected cells, it also would be interest-
ing to test the gp140 variants in our CDV vector platform tocompare the proﬁle of immune responses induced by a soluble
subunit vaccine and a mucosally-delivered replicating vector.
To lessen the attenuating effect of adding a foreign gene to CDV,
we ﬁrst tested insertion of the SIV Env gene into the 4th genomic
position anticipating that this would minimally disrupt expression
of the N, P, and M transcription units. Insertion of the Env gene in
positions 1–3 closer to the promoter were not tested because we
anticipated that signiﬁcant vector attenuation would result as
shown to occur for other negative stranded RNA viral vectors
(Roberts and Rose, 1998; Zhao and Peeters, 2003). Initially, we
were unable to recover a recombinant virus expressing gp160 and
later found that removal of most of the Env CT was necessary. We
concluded that the CT was probably inhibiting vector replication
since it has a known inhibitory role in cells infected with SIV or
HIV (Ritter Jr. et al., 1993; Zingler and Littman, 1993) and has been
problematic in other vector systems (Jurgens et al., 2012; Wyatt
et al., 2008) including our own experience with VSV vectors
(unpublished lab observation), which have tended to introduce
translation stop codons that truncate the CT and retain just 2–9
amino acids of the CT domain after several rounds of propagation.
Although the rCDV-SIVEnvΔct4 was viable, attempts to pro-
pagate the virus under a variety of conditions such as different
multiplicity of infection (MOI) or lower temperatures did not
improve replication in Vero cells. Since robust rCDV vector
propagation on Vero cells is dependent on efﬁcient expression
of its two membrane glycoproteins, F and H, lack of F protein
expression in infected cells (Fig. 4) probably accounted for the
poor growth of rCDV-SIVEnvΔct4 vector on this cell line. Consis-
tent with this conclusion, we also generated an rCDV encoding
uncleavable SIV EnvΔct in the 4th position of the CDV genome,
and this virus also was viable but grew poorly (data not shown),
indicating vector design and not Env function was the cause of the
inhibitory effect. Improved propagation of rCDV-SIVEnvΔct4
encoding functional Env was observed on CD4+/CCR5+ GHOST
cells likely indicating that the vector used Env to promote spread
in the cell monolayer since the abundance of F was very limiting.
Finding that SIVEnvΔct4 viruses could be rescued despite the
growth defect probably reﬂects the fact that the rescue system we
use includes plasmid DNA expressing F, which provided genetic
complementation.
The mechanism responsible for the signiﬁcant reduction in F
protein expression in the rCDV-SIVEnvΔct4 vectors is unclear.
Some reduction of F expression was expected because a gene
was added upstream of F (Whelan et al., 2004); however, this does
not seem to fully account for the very low quantities of F protein
seen in infected cells. Perhaps, our SIVEnvΔct4 gene insertion
strategy was responsible for the F expression defect. When Env
coding sequences were inserted in position 4, it replaced the F
coding sequence, which resulted in the Env gene being joined to
the long F untranslated region (UTR). As a result the F gene
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the natural boundary between F/H were used to control F gene
expression. One consequence of this is that the F mRNA no longer
contained a long UTR. This may have contributed to suppression of
F protein expression, as the long M/F intergenic region is uniquely
conserved and is known to control expression (Anderson and von
Messling, 2008).
In contrast to the poor replication of the rCDV-SIVEnvΔct4
vectors, both rCDV-SIVEnvΔct6 and rCDV-SIVEnvΔct6UNC dis-
played growth kinetics on Vero cells similar to rCDV vector
without an insert. Since our intent was to construct vectors that
were replication-competent, we focused on further development
and characterizations of these candidate vaccines. Analysis of the
cellular distribution of Env by confocal microscopy showed that
both cleavable and uncleavable SIV EnvΔct were displayed on
infected cell surface. Moreover, Env was present in virus particles
and SIVEnvΔct6 could mediate CD4/CCR5 coreceptor-dependent
infection (Fig. 6). Thus, at least some of the Env incorporated in
CDV particles likely maintained trimeric conﬁguration similar to
functional Env found on live SIV particles. Maintaining function is
an indicator that at least some expressed Env is processed and
assembled into the correct trimeric conﬁguration, which is impor-
tant for this immunogen since it is known that some potent HIV
neutralizing antibodies are speciﬁc for quaternary structures
found in the trimeric spikes (Kwong and Mascola, 2012; Schief
et al., 2009). In fact, the ferret data indicated that functional SIV
Env encoded by the rCDV-SIVEnvΔct6 elicited antibodies capable
of neutralizing SIV pseudoviruses.
Ferrets were used to examine replication and immunogenicity
of rCDV-SIVEnv vectors. Ferrets are naturally susceptible to CDV
infection and can serve as an important model to characterize
rCDV vectors. We focused on testing the rCDV-SIVEnvΔct6 vector
since it encoded functional Env and also propagated relatively
efﬁciently in Vero cells. Intranasal instillation was studied because
CDV naturally infects through aerosol transmission and we
wanted to use this vaccination route in the future to help stimulate
mucosal immunity, which has proven effective in mucosal
vaccines controlling polio, inﬂuenza, and rotaviral diseases
(Barria et al., 2013; Glass et al., 2006; Lycke, 2012; Sabin, 1985).
No adverse effects were observed in any of the vaccinated ferrets,
which was expected since our vector was derived from a canine
vaccine strain, which is also used to vaccinate domesticated ferrets
(Wimsatt et al., 2001). Infectious rCDV-empty or rCDV-SIVEnvΔct6
was not detected in tissues at DPI 1 in any animals, but was
recovered at DPI 7 from intestine rich in Peyer's patches and MLN,
indicating that virus spread from the nasal cavity to the GALT. Lack
of virus in tissues at DPI 21 correlated with rising CDV neutralizing
antibody titers from DPI 7 to 21. Similar quantities of neutralizing
antibodies were induced by rCDV-empty and rCDV-SIVEnvΔct6
(Table 2) suggesting that Env gene insertion did not signiﬁcantly
attenuate rCDV vector immunogenicity. Although the quantity of
antibodies induced by rCDV-empty and rCDV-SIVEnvΔct6 vectors
was similar, there was notable animal-to-animal variation in the
quantity of virus isolated from tissues (Table 1), which probably
reﬂects the fact that these are outbred ferrets. Lack of a direct
correlation between the magnitude of replication and the induced
humoral response also has been observed with attenuated MeV
(Leonard et al., 2010).
In conclusion, we developed CDV vectors encoding SIV Env
as an integral membrane protein. A CDV vector encoding Env in a
functional form was immunogenic, safe, and capable of inducing
neutralizing antibodies when administered to ferrets by intranasal
drops. Development of a replication-competent vector required Env
CT truncation and insertion of the Env gene speciﬁcally between
the CDV H and L genes. Future studies will include construction of
vectors encoding additional SIV proteins and testing rCDV-SIVvaccines in macaques to determine if they replicate without causing
adverse reactions and induce SIV-speciﬁc immune responses.Materials and methods
Cell culture
Vero, HOS, and 293-T cells were maintained in Dulbecco's
modiﬁed Eagle's medium (DMEM, Gibco) supplemented with
10% fetal bovine serum. The GHOST cell line is a derivative of
HOS that express human CD4/CCR5 (Cecilia et al., 1998). GHOST
cells were maintained in the DMEM supplemented with Geneticin
(Life Technologies).
Molecular cloning and recombinant CDV vector construction
Molecular cloning was performed following standard protocols
(Maniatis et al., 1982). Plasmids Bluescript II SK (+/) (Stratagene,
La Jolla, CA, USA) and pCI-Neo (Promega) were used for construct-
ing the rCDV genomic clone and expression vectors encoding CDV
structural protein, respectively.
A live-attenuated CDV vaccine based on the Onderstepoort
strain (Haig, 1948) was purchased from a veterinary supplier and
was used as the starting source for isolating attenuated CDV.
Vaccine virus was serially passaged 10 times on Vero cell mono-
layers before 3 rounds of plaque puriﬁcation were performed to
derive a clonal isolate. The genomic sequence of the plaque-
puriﬁed virus was determined by extracting RNA, performing
reverse transcription and PCR (RT-PCR) using primers based on
the CDV nucleotide sequence in GenBank (accession number
AF014953), and performing DNA sequencing on ampliﬁed DNA
fragments. To construct a genomic cDNA clone, 8 overlapping DNA
fragments were ampliﬁed from viral RNA extracted from the
plaque-puriﬁed virus using the SuperScript™ III One-Step RT-PCR
system (Invitrogen, USA). The cDNA fragments were cloned into
pCR-TOPO (Invitrogen, USA) after which their sequence was
conﬁrmed. The 8 cloned fragments were then assembled into a
full-length genomic clone in pBluescript II SK (+/) (Stratagene, La
Jolla, CA, USA) 3′ to the T7 promoter. The T7 promoter was
truncated to 17nt (TAATACGACTCACTATA) to direct transcript
initiation at the 5′ end of the CDV antigenome (Sidhu et al.,
1995). Hepatitis D virus ribozyme and T7 polymerase terminator
sequences were inserted downstream of the antigenome to
promote formation of the correct 5′ terminus of a genomic
transcript (Sidhu et al., 1995). PacI and NotI sites were introduced
into the genomic clones either upstream of F (i.e. 4th gene
position, Fig. 1) or downstream of H (i.e. 6th gene position) for
SIV Env gene cloning.
A plasmid DNA containing an RNA-optimized SIVmac239 Env
coding sequence was obtained from Drs. George Pavlakis and
Barbara Felber at National Cancer Institute, USA (Rosati et al.,
2009). For Env lacking the CT, nucleotides encoding the C-terminal
159 amino acids were removed leaving coding sequence for only a
short 5 amino acids cytoplasmic domain. To make an uncleavable
Env, the furin protease cleavage motif R N K R between amino
acid 522 and 525 of SIVEnv was changed to S N K S. The relevant
coding sequence mutations were introduced using the PCR-based
QuikChage site-directed mutagenesis kit following the manufac-
turer's instructions (QuikChange Site-directed Mutagenesis kit,
Stratagene). A conserved Kozak sequence (AGGAGCCACC) was
added 5′ of the AUG translation initiation codon of Env (Kozak,
1999). Transcription stop and start sequences derived from the
CDV F–H intergenic region were used to control Env expression in
the 4th or 6th genomic position (Fig. 1). The long F untranslated
sequence was maintained in the 4th genomic position and
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this position. The Env genes were inserted into the genomic clone
using unique PacI and NotI sites described above.
A genomic cDNA clone was generated containing a green
ﬂuorescence protein (GFP) coding sequence upstream of N (i.e.
1st genomic position). N–P intergenic region sequences were
placed between the GFP and N gene. The encoded protein corre-
sponds to a GFP sequence in GenBank (accession number
ACV74423). The rCDV-GFP virus was used in the virus neutraliza-
tion assay described below.
Plasmid vectors needed for virus rescue that express CDV
structural proteins (N, P, M, F, H and L) were constructed using
pCI-Neo (Promega), which was modiﬁed ﬁrst by deleting the T7
RNA polymerase promoter. To improve protein expression, genes
coding the CDV structural proteins were optimized to contain
high frequency codons using the GeneDesign Program (Richardson
et al., 2006). In addition, potential mRNA splicing sites were
identiﬁed using a splicing signal prediction tool (Reese et al.,
1997) after which they were disrupted by substituting synon-
ymous codons. A Kozak element (AGGAGCCACC) was added 5′ to
the translation initiation codon and nucleotide homopolymer
stretches of greater than 5 nucleotides were interrupted using
synonymous codons. The T7 bacteriophage RNA polymerase
(pCMV-T7) expression plasmid used for virus rescue contained
the phage gene inserted into the modiﬁed pCI-Neo vector.
Rescue of recombinant CDV from plasmid DNA was performed
according to published procedures with some modiﬁcations (Parks
et al., 2002; Witko et al., 2006). Brieﬂy, 293-T cells in 6-well plates
were fed 0.5–3 h before transfection with 2 ml of DMEM contain-
ing 10% fetal bovine serum and transferred from a 37 1C to a 32 1C
incubator. Cells were transfected with 5 μg rCDV genomic cDNA
construct, 1.6 μg pCMV-CDV(N), 1.2 μg pCMV-CDV(P), 0.15 μg each
for pCMV-CDV(M), pCMV-CDV(F), pCMV-CDV(H), 0.4 μg pCMV-
CDV(L), and 5 μg pCMV-T7 using calcium-phosphate reagents
obtained from a commercial supplier (Clonetech, USA). Three
hours after initiating transfection, the cells were subjected to
43 1C heat shock for 1.5 h before returning the cells to a 32 1C
incubator. After overnight incubation, the transfection medium
was replaced with fresh medium. At 72 h post transfection, the
transfected cells were scraped into the culture medium and then
transferred to six-well plates containing a 50–70% conﬂuent Vero
cell monolayer. The cocultured cells were incubated at 37 1C for
3 h before replacing the medium. CPE indicative of virus infection
usually appeared after 2 to 3 rounds of coculture. Rescued viruses
were plaque puriﬁed 3 times and then expanded on Vero cells. For
virus expansions, Vero cells were infected at MOI of 0.02 in Nunc
ﬂasks (Thermo Scientiﬁc, USA). Cell monolayers were incubated
with viral inoculums for 1 h before medium was replaced with
fresh DMEM. When maximal CPE was reached, infected cells were
scraped into the culture medium after which the suspension was
subjected to two freeze/thaw cycles. The virus suspensions were
then clariﬁed and plaque forming units (PFU) were quantiﬁed on
Vero cell monolayers as described below.
Viral protein expression evaluated by immunostaining, confocal
microscopy and Western blot
Infection of Vero, GHOST, and HOS cells with an early-passage
rCDV-SIVEnvΔct4 was performed to compare CPE. Supernatant
(0.1 ml) from 293-T cells cocultured with Vero cells were used to
infect fresh cell monolayers cultured in 6-well plates. At 1 DPI (for
GHOST) and 3 DPI (for Vero and HOS), the medium was removed
and the adherent infected cells were immunostained by ﬁrst ﬁxing
cells with cold 100% methanol for half an hour, blocking for 1 h
with 1% non-fat dry milk (NFDM) prepared in PBS buffer, and then
incubating for 1 h with primary anti-CDV N monoclonal antibody(LifeSpan) or SIVEnv-speciﬁc antibody KK65 targeting gp120 V1
region (NIH AIDS Research and Reference Reagent Program). These
primary antibodies were used at 1 to 1000 dilution prepared in
PBS buffer containing 0.5% NFDM and 0.05% Tween-20. Subse-
quently, cells were washed 3 times with PBS buffer containing 0.1%
Tween-20 and were then incubated with HRP conjugated anti-
mouse or anti-monkey secondary antibodies (Santa Cruz) at 1 to
1000 dilution in PBS buffer containing 0.5% NFDM and 0.05%
Tween-20. After washing 3 times with 0.1% Tween-20 PBS buffer,
antibody binding was detected by HRP-speciﬁc 3-Amino-9-
ethylcarbazole (AEC) substrate staining (Sigma).
To evaluate plasma membrane bound SIV Env, confocal micro-
scopy was conducted using infected Vero cells. The cells were
cultured in chamber slides and infected with rCDV-SIVEnvΔct6 or
rCDV-SIVEnvΔct6UNC (Fig. 1). The slides were ﬁxed in freshly
prepared 2% paraformaldehyde (PFA) in PBS for 30 min. The slides
were blocked for 1 h at room temperature with 10% goat serum,
which was prepared in PBS with or without 0.1% Triton X100
for preparation of permeabilized or nonpermeabilized cells,
respectively. Following the blocking step, the cells were stained
for 30 min according to manufacturer's protocol with Alexa Fluor-
488 Phaloidin (Invitrogen), which is an F-actin binding peptide.
After washing twice with PBS, slides were incubated overnight
at 4 1C with the primary monoclonal antibody SIVmac251 gp160/
gp120 (KK17) that was diluted 1:100 in sample buffer (PBS
containing 1% goat serum and +/ Triton X100). The primary
antibody solution was then removed and the cells were washed
with PBS after which they were incubated at room temperature for
1 h with Alexa Fluor-647 labeled goat anti-mouse IgG2a secondary
antibodies (1:500) in the sample buffer. After three rounds of
washing with PBS, the slides were rinsed with deionized water,
quickly dried and mounted using Vectorshield Mounting Medium
(Vector Laboratories) for ﬂuorescence with DAPI. Z-stack images
were then acquired covering whole thickness of cells on the slides
and images were analyzed and projected to a composite picture by
immuno-ﬂuorescence microscopy (IFM) using a 4 laser Olympus
microscope equipped with a Yokagama Confocal Scanning Unit
(CSU)-X1.
Western blotting was used to analyze cell-free and cell-
associated viral proteins produced from infected cells. GHOST
and Vero cells were used for infection with rCDV-SIVEnvΔct6
and rCDV-SIVEnvΔct6UNC, but only data from GHOST cell infec-
tion is shown for rCDV-SIVEnvΔct4 since this virus replicated
poorly in Vero cells. Western blot analysis is not shown for cells
infected with rCDV-SIVEnvΔct4UNC because this virus propagated
poorly in both Vero and GHOST cells. For cell-free viral protein
analysis, cell monolayers were infected at MOI of 0.02. Culture
supernatants were collected when CPE was observed through
most of the cell monolayer. The harvested supernatant was
clariﬁed by centrifugation before samples were analyzed by
Western blotting. For the analysis of cell-associated viral proteins,
Vero or GHOST cell monolayers were infected in 6-well plates at
MOI of 0.1. At approximately 24 HPI, when syncytium and CPE
started appearing, the medium was aspirated and infected cells
were lysed with 500 μl of lysis buffer (CelLytic™ M, Sigma)
supplemented with protease inhibitor (Sigma). Cell debris was
cleared by centrifugation and samples of the supernatant were
mixed with LDS loading buffer (Invitrogen) containing dithiothrei-
tol before incubation for 10 min at 85 1C. Denatured protein was
electrophoresed on 4–12% Bis-Tris polyacrylamide gel (Invitrogen)
before transfer to nitrocellular membrane (Invitrogen). The blots
were probed with antibodies recognizing SIV Env (KK65 from NIH
AIDS Research and Reference Reagent Program), monoclonal anti-
CDV nucleoprotein (LifeSpan), a polyclonal rabbit anti-CDV matrix
protein, or a rabbit serum recognizing extreme C-terminal 14 aa of
CDV F protein (von Messling et al., 2004b). After incubation for 1 h
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containing 0.05% Tween-20 and were then incubated with respec-
tive HRP-conjugated anti-mouse or anti-rabbit IgG secondary
antibodies (Santa Cruz, California, USA). Western blot signals were
detected with Enhanced ChemoLuminescence (ECL)-Substrate (GE
Healthcare Bio-Sciences Corp., Piscataway, New Jersey, USA). All
Western images were evaluated using a bioimager (Bio-Rad,
Hercules, California, USA) or X-ray ﬁlm (Kodak).
In vivo studies
CDV vectors used in ferret studies were plaque-puriﬁed isolates
that were ampliﬁed by infecting Vero cell monolayers at MOI of
0.02. Medium supernatants were harvested when CPE was evident
nearly 100% of the monolayer and then clariﬁed at 800 g for
10 min at 4 1C. Vectors were then puriﬁed and concentrated by
2 consecutive rounds of centrifugation through 20% sucrose
(prepared in PBS). Virus pellets were resuspended in PBS contain-
ing 3% Sucrose before being stored at 80 1C. The quality of the
vector used for ferret studies was assessed by (1) determining
infectious units by plaque assay (see below); (2) conﬁrming insert
integrity by RT-PCR; (3) determining the nucleotide sequence of
the Env insert; and (4) evaluating Env expression in infected cell
monolayers by immunostaining and Western blotting.
All animal care procedures took place at the State University of
New York, Downstate Medical Center and conformed to Institu-
tional Animal Care and Use Committee (IACUC) guidelines. Fifteen
out-bred ferrets (Mustela putorius furo), which were withheld
from routine CDV vaccination, were obtained from Triple F Farms
(Sayre, PA) at 10–12 weeks of age. The animals were housed
in groups of two to three animals in ventilated isolator cages
(Allentown Inc., Allentown, NJ) and acclimated for 1 week prior to
the initiation of the study procedures. Transponders (BioMedic
Data Systems, Rockville, MD) used to identify ferrets and record
body temperatures were inserted subcutaneously into the nape of
the neck of each animal. Baseline blood samples were collected
from sedated animals via the cephalic or jugular vein. Sera were
conﬁrmed negative for CDV neutralizing antibodies prior to inocu-
lation by rCDV-GFP neutralizing assay (see below). Intranasal
drops containing CDV were administered to ferrets anesthetized
with a combination of Ketamine and Dexdomitor each at 25 mg/kg
body weight. The anesthetized animals were instilled intranasally
with either 1107 PFU of rCDV-SIVEnvΔct6 (n¼6), 1107 PFU of
rCDV-empty (n¼6), or no virus (n¼3) in 100 ul PBS containing 3%
Sucrose (50 ul per nare). Animals were observed daily for tem-
perature elevations and any physical or behavioral signs of
CDV infection; none were noted. At 1, 7, and 21 DPI, one third of
the animals in each group were euthanized and terminal blood
collection was performed via cardiac puncture. At necropsy, nasal
turbinate (NT), the large mesenteric lymph node (MLN), and a
2–3 in. section of the intestine that appeared rich in Peyer's
patches (PP) were harvested.
Virus assays
Vero cell monolayers cultured in 6-well plates were used to
quantify CDV by plaque assay. Virus was diluted serially in DMEM
then applied to duplicate wells containing approximately 85%
conﬂuent monolayers. After 1 h of virus absorption, the infecting
medium was removed and the cells were overlayed with 2 ml
DMEM containing 0.75% methylcellulose. At 3–5 DPI, infected cell
monolayers were ﬁxed with 100% methanol for 30 min, washed
with PBS, blocked with PBS containing 1% NFDM and incubated
with anti-CDV N monoclonal antibody (LifeSpan). After removing
the primary antibody and washing the cells with PBS, diluted anti-
mouse secondary antibody-HRP was applied for 1 h. AEC substratewas added after the secondary antibody was removed and the
cells were washed with PBS. Plaques were counted under inverted
light microscope and PFU/ml titers were calculated.
Growth kinetics for rCDV, rCDV-SIVEnvΔct6, and rCDV-SIVEnvΔc-
t6UNC were determined using Vero cells cultured at 37 1C and 5%
CO2. Cells in 6-well plates were infected at MOI of 1 in duplicate.
Medium supernatants and cells were harvested every 12 HPI by
scraping cells into the culture medium and subjecting the suspension
to two rounds of freeze/thaw before clarifying the lysates by
centrifugation. Infectious titers were determined by plaque assay as
described above.
To evaluate CD4/CCR5 dependent infection, virus was incu-
bated (1 h, 37 1C) with neutralizing quantities of anti-CDV ferret
serum. After incubation, the virus/serum mixture was applied to
GHOST cells and Vero cells. At 24 HPI, cells were ﬁxed and stained
with anti-CDV N monoclonal (LifeSpan) to conﬁrm infection.
To detect virus in ferret tissues, the nasal turbinates, mensenteric
lymph nodes, and large intestine containing Peyer's patches were
weighed and homogenized with saw-tooth rotor-stator generator
probes (Omni International, Kennesaw, GA) in SPG buffer (0.2 M
sucrose, 7.0 mM K2HPO4, 3.8 mM KH2PO4, 5.0 mM glutamic acid) to
achieve 10% weight/volume solutions. Homogenates were clariﬁed
by low-speed (2000 rpm) and then high speed (14000 rpm) centri-
fugation, aliquoted, and stored at 80 1C. Vero cells were seeded one
day earlier in 6-well plates for conducting infections with tissue
homogenates and were approximately 85% conﬂuence at time of use.
Immediately before infection, mediumwas replaced with 0.5 ml/well
of DMEM (Gibco) supplemented with antibiotics, glutamine and
2.5 mg/ml Amphotericin B solution (Sigma) for inhibiting fungal
growth. One hundred microliters of undiluted tissue homogenates
were inoculated in duplicate wells and incubated for 1 h before the
medium was changed to DMEM containing 0.75% Methylcellulose
(Sigma), 10% FBS, and 2.5 mg/ml Amphotericin B solution. Plates
were kept for 5 days before they were ﬁxed with cold methanol
and stained with anti-CDV N monoclonal antibody (LifeSpan). After
incubation with anti-mouse secondary antibody-HRP conjugates
followed by AEC substrate detection, plaques were counted under
an inverted light microscope. Virus titers were expressed as PFU per
gram of tissue.
Ferret serum antibody titration
CDV-speciﬁc neutralizing antibody titers were determined
using an rCDV-GFP reporter virus. Ferret serumwas ﬁrst incubated
at 56 1C for 30 min and was then diluted serially in serum-free
DMEM from 1:4 to 1:16,384 in quadruplicates. Subsequently 25 ml
of rCDV-GFP (100 PFU) was mixed with 25 ml of diluted serum;
thus the serum dilution series started at a 1:8 dilution. The serum/
virus mixtures were incubated for 1 h at 37 1C before being
applied to Vero cell monolayers prepared in serum-free DMEM
in 96-well plates. After 2 h incubation, the medium was replaced
with 200 ml of DMEM containing 10% fetal calf serum. The plates
were incubated for 5 days before counting GFP-positive wells.
Neutralizing antibody titers were expressed as the reciprocal of
the highest serum dilution at which green ﬂuorescence is com-
pletely inhibited in all 4 replicate wells. Immune ferret serum was
used as a positive control and CDV-GFP infection conducted in the
absence of ferret serum was the negative control.
Immunostaining and ELISA were used to detect SIV Env-speciﬁc
antibodies in ferret sera. Neutralizing antibodies speciﬁc for SIV
also were detected using pseudoviruses prepared with SIV Env and
the reporter cell line on TZM-bl (Hoffenberg et al., 2013). For
immunostaining, GHOST cell monolayers were infected with a
replication-competent chimeric vesicular stomatitis virus (VSV)
vector that encodes SIVmac239 Env in place of VSV G (VSV-ΔG-
SIVenv). At 24 HPI, the infected monolayers were ﬁxed with 100%
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temperature with PBS containing 1% NFDM. The ﬁxed cells were
then incubated with diluted ferret serum (1:100) collected on day
21 after vaccination with the rCDV-empty or rCDV-SIVEnvΔct6.
After 1 h incubation at room temperature, the cells were washed
with PBS containing 0.05% Tween-20 before adding a solution
containing anti-ferret IgG-HRP conjugate (Bethyl, USA) and incu-
bating for 1 h. A staining kit was used (AEC kit, Sigma, USA) to
detect HRP. For ELISA, SIVEnv-speciﬁc binding antibodies in sera
were captured with SIVEnv gp130 that was absorbed by the plate
according to published procedures (Winstone et al., 2011). Serum
was serially diluted in 5-fold increments in PBS containing 1%
NFDM and added to plates coated with SIVEnv gp130. Serum
antibody bound to SIV Env gp130 was detected by goat anti-ferret
IgG-HRP conju-
gate (Bethyl, USA) followed by development with 3, 3′, 5,
5′-Tetramethylbenzidine (TMB) substrate (Biolegend, USA). Optical
density (OD) was measured at 450 nm using SoftMAx Pro GxP v5
(Molecular Devices, USA). For detecting SIV neutralizing anti-
bodies, SIV pseudoviruses were produced by cotransfecting
293T/17 cell monolayers with plasmid encoding SIV Env and
the HIV pseudovirus genomic RNA. Infectious pseudoviruses
were prepared with SIV Env from neutralization-sensitive SIV
strain (SIVsmE660/CG7G), a more neutralization resistant SIV
Env (SIVsmE660/CG7V) (Lopker et al., 2013), or a control murine
leukemia virus (MLV) envelop glycoprotein. Pseudovirus titers
were determined using TZM-bl reporter cells line (Hoffenberg
et al., 2013). To quantify neutralization, pseudoviruses at a dose
that produced 150,000 relative light unites (RLU) was incubated
with 4-fold serially diluted ferret serum post heat-inactivation.
TZM-bl cells were then infected with the pseudoviruses and RLUs
were quantiﬁed 48–72 h later. For each ferret, both terminal and
pre-vaccination sera were measured. Post-vaccination serum neu-
tralization activity at each dilution was expressed as (1terminal
bleed RLU/pre-vaccination bleed RLU)100. Values were ﬁt to
3-parameter curves and ID50 titers were interpolated using
Graphpad Prism 6.0.Acknowledgments
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